Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2

BACKGROUND: The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy, significantly improves survival of women with resected, HER2-overexpressing breast cancers, but is associated with toxicities including a risk of cardiomyopathy. Additionally, the beneficial effect of trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Morse, Michael A, Hobeika, Amy, Osada, Takuya, Niedzwiecki, Donna, Marcom, Paul Kelly, Blackwell, Kimberly L, Anders, Carey, Devi, Gayathri R, Lyerly, H Kim, Clay, Timothy M
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042490/
https://www.ncbi.nlm.nih.gov/pubmed/17822557
http://dx.doi.org/10.1186/1479-5876-5-42

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042490/
https://www.ncbi.nlm.nih.gov/pubmed/17822557
http://dx.doi.org/10.1186/1479-5876-5-42

Ejemplares similares